191 – 200 of 459
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Characterization of PSA in clinical samples by mass spectrometry
2010) 4th EuPA Scientific Meeting - A Proteomics Odyssey Towards Next Decades In [Publication information missing] p.508-510(
- Contribution to journal › Published meeting abstract
-
Mark
Mass spectrometric strategy for clearcut identification of prostate specific antigen in clinical Samples
2010) 4th EuPA Scientific Meeting - A Proteomics Odyssey Towards Next Decades In [Publication information missing] p.114-117(
- Contribution to journal › Published meeting abstract
-
Mark
Characterization of PSA in clinical samples by mass spectrometry
2010) Swedish Proteomics Society Symposium, 2010(
- Contribution to conference › Abstract
-
Mark
Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
(
- Contribution to journal › Article
-
Mark
A Common Prostate Cancer Risk Variant 5 ' of Microseminoprotein-beta (MSMB) Is a Strong Predictor of Circulating beta-Microseminoprotein (MSP) Levels in Multiple Populations
(
- Contribution to journal › Article
-
Mark
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer : Case-control study
(
- Contribution to journal › Article
-
Mark
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up : An independent validation study from the European Randomized Study of Prostate Cancer screening, France
(
- Contribution to journal › Article
-
Mark
The relationship between prostate-specific antigen and prostate cancer risk : The prostate biopsy collaborative group
(
- Contribution to journal › Article
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
(
- Contribution to journal › Article